Etiological and non-etiological therapies for cirrhotic portal hypertension

VernacularTitle:肝硬化门静脉高压的病因和非病因治疗
Author: Yuerong LI ¹ ; Min WANG ¹ ; Fuliang HE ¹ ; Xinyan ZHAO ¹ ; Xiaojuan OU ¹ ; Hong YOU ¹ ; Jidong JIA ¹ ; Yu WANG ¹
Author Information

1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Beijing 100050, China
Publication Type:Discussions by Experts
Keywords: Liver Cirrhosis; Portal Hypertension; Therapeutics
From: Journal of Clinical Hepatology 2022;38(6):1224-1228
CountryChina
Language:Chinese
Abstract: Portal hypertension is a serious complication of liver cirrhosis resulting from the increases in portal vascular resistance and portal blood inflow. Both etiological and non-etiological therapies can effectively reduce portal venous pressure to a certain degree, but with an unsatisfactory effect in improving prognosis. New therapeutic drugs targeting the reduction in intrahepatic vascular resistance may help to achieve the reversal of portal hypertension. Based on the pathogenesis of cirrhotic portal hypertension, this article summarizes the current pharmacotherapies from the aspects of etiological and non-etiological therapies, so as to provide a comprehensive theoretical and evidence-based basis for clinical treatment options.